Spec Dr. Elkhan Mammadov, Oncologist - Baku, Azerbaijan

Spec. MD. Elkhan Mammadov is a highly distinguished Medical Oncology Specialist currently practicing at Liv Hospital. With a profound commitment to advancing cancer care, Dr. Mammadov has dedicated his medical career to the accurate diagnosis and comprehensive treatment of various oncological conditions. His extensive medical background seamlessly bridges the gap between internal medicine and specialized oncology, allowing him to approach cancer treatment with a deep, holistic understanding of the human body and its complex systemic responses to both disease and advanced therapeutic interventions.

At Liv Hospital, Dr. Mammadov leverages state-of-the-art medical technologies and evidence-based protocols to deliver personalized care to each patient. His clinical focus encompasses a wide spectrum of modern oncological treatments, including cytotoxic chemotherapy, hormone therapy, advanced targeted therapies (smart drugs), and groundbreaking immunotherapy. By integrating these cutting-edge modalities, he strives to provide optimal clinical outcomes and improve the quality of life for patients battling complex malignancies. His extensive participation in global Phase III clinical trials further underscores his position at the forefront of modern cancer research and innovative therapeutic development.

Medical Expertise & Specializations

Spec. MD. Elkhan Mammadov is globally recognized for his comprehensive expertise in the field of medical oncology. His approach to cancer care is deeply rooted in precision medicine, utilizing the latest advancements in molecular biology and immunology to target cancer cells effectively while minimizing the impact on healthy tissues. Dr. Mammadov's therapeutic arsenal is vast, allowing him to tailor highly individualized treatment regimens based on the unique genetic makeup of a patient's tumor and their overall clinical profile.

His clinical practice is heavily focused on the implementation of targeted therapies—often referred to as "smart drugs"—which specifically attack the genetic mutations driving cancer growth. Additionally, he is an expert in immunotherapy, a revolutionary treatment modality that empowers the patient's own immune system to recognize and destroy malignant cells. Through his meticulous administration of cytotoxic chemotherapy and hormone therapies, Dr. Mammadov provides a multi-disciplinary, robust defense against aggressive and advanced-stage cancers.

Conditions Treated

Through his extensive clinical practice and robust background in international clinical trials, Dr. Mammadov has developed profound expertise in managing a variety of complex oncological conditions, including but not limited to:

• Non-Small Cell Lung Cancer (NSCLC): Including cases with specific genetic mutations such as EGFR Exon 20 insertions.
• Small Cell Lung Cancer (SCLC): Management of both limited-stage and extensive-stage small cell lung cancer.
• Breast Cancer: Treatment of advanced, unresectable, or metastatic Triple-Negative Breast Cancer, as well as Hormone Receptor-Positive (HR+)/HER2-Negative advanced breast cancer.
• Endometrial Cancer: High-risk endometrial cancer requiring rigorous postoperative treatment protocols.
• Essential Thrombocythemia: Management of rare blood cancers and myeloproliferative neoplasms.
• Locally Advanced and Metastatic Malignancies: Comprehensive care for cancers that have spread beyond their primary origin.

Procedures & Treatments Performed

As a premier medical oncologist at Liv Hospital, Dr. Mammadov utilizes an array of sophisticated systemic treatments to combat cancer:

• Advanced Cancer Diagnosis and Staging: Utilizing comprehensive clinical and laboratory findings to accurately stage and type malignancies.
• Cytotoxic Chemotherapy: Administration of systemic medications to destroy rapidly dividing cancer cells.
• Targeted Therapy (Smart Drug Therapy): Precision treatments designed to interfere with specific molecules necessary for tumor growth and progression.
• Immunotherapy: Utilizing the body's immune system to fight cancer, utilizing monoclonal antibodies and checkpoint inhibitors.
• Hormone Therapy: Prescribing treatments that slow or stop the growth of cancers that use hormones to grow, predominantly in breast cancer.

Education and Professional Training

Dr. Elkhan Mammadov’s exceptional clinical skills are built upon a foundation of rigorous academic training and continuous medical education at some of the most prestigious medical institutions in the region. His chronological educational background highlights a deep dedication to mastering the complexities of internal medicine and oncology.

• 2004 - 2010: Medical Degree, Azerbaijan Medical University
• 2014 - 2019: Internal Medicine Specialist Residency, Istanbul University, Istanbul Faculty of Medicine
• 2019 - 2022: Oncology Subspecialty Training, Istanbul Medipol Mega University Hospital

His specialization thesis, titled "Evaluation of Clinical and Laboratory Findings and Treatment Outcomes in Patients Diagnosed with Essential Thrombocythemia," reflects his deep investigative approach to complex hematological and oncological conditions.

Publications, Research, and Clinical Trials

Dr. Mammadov is not only a practicing clinician but also a dedicated clinical researcher. He has played a crucial role in numerous high-profile, international Phase III clinical trials. These studies are vital for bringing new, life-saving oncology drugs to the global market. His involvement in these trials ensures that he remains at the absolute cutting edge of oncological science.

Key Clinical Research Contributions Include:

• Phase III randomized studies comparing combination therapies (such as Amivantamab and Lazertinib) for EGFR-mutated locally advanced or metastatic Non-Small Cell Lung Cancer.
• Double-blind, placebo-controlled trials evaluating combinations like Ipatasertib, Atezolizumab, and Paclitaxel in patients with unresectable or metastatic Triple-Negative Breast Cancer.
• Research evaluating Pembrolizumab (MK-3475) in combination with concurrent chemoradiation therapy for untreated, limited-stage Small Cell Lung Cancer.
• Phase III trials exploring adjuvant Durvalumab in combination with platinum-based chemotherapy for completely resected Stage II-III Non-Small Cell Lung Cancer.
• Studies evaluating the efficacy and safety of GDC-9545 and Palbociclib in locally advanced or metastatic Hormone Receptor-Positive, HER2-Negative breast cancer.
• Phase 3 studies comparing Pembrolizumab with adjuvant chemotherapy in the postoperative treatment of newly diagnosed high-risk endometrial cancer.
• Descriptive studies of PIK3CA mutations in HR+/HER2- advanced breast cancer patients.
• Phase III studies involving recombinant humanized anti-PD-1 monoclonal antibodies in combination with chemotherapy for advanced squamous non-small cell lung cancer.

Professional Memberships

To continuously provide the highest standard of care and remain actively engaged with the global oncological community, Dr. Mammadov holds active memberships in premier international and regional medical associations:

• ASCO: American Society of Clinical Oncology
• ESMO: European Society for Medical Oncology
• Turkish Medical Oncology Association

Frequently Asked Questions (FAQ)

Take the First Step Toward Advanced Cancer Care

Facing a cancer diagnosis is overwhelming, but you do not have to navigate it alone. Accessing cutting-edge treatments like targeted therapy and immunotherapy requires a world-class specialist. PlacidWay partners with globally recognized medical experts like Spec. MD. Elkhan Mammadov at Liv Hospital to ensure you receive the most advanced and personalized oncological care available.

Contact PlacidWay today to schedule your comprehensive medical consultation with Dr. Elkhan Mammadov. Our dedicated team will assist you in arranging your appointments, facilitating medical record transfers, and planning your medical journey, allowing you to focus entirely on your health, treatment, and recovery.